Additionally, KMT2A-MAML2 translocation has been observed in 6% of clinically invasive type B2 and B3 thymomas, as well as in one case of combined thymic carcinoma (type B3 thymoma with small thymic carcinoma component). This evidence concerns the gene MAML2 and thymic carcinoma.